Palvella Therapeutics price target raised to $80 from $56 at Truist
PositiveFinancial Markets

Palvella Therapeutics has received a significant boost as Truist raises its price target from $56 to $80. This adjustment reflects growing confidence in the company's potential and its innovative treatments. Investors and stakeholders should take note, as this could indicate a promising future for Palvella in the competitive pharmaceutical landscape.
— Curated by the World Pulse Now AI Editorial System